Fulcrum Therapeutics (FULC) Net Cash Flow (2018 - 2026)
Fulcrum Therapeutics (FULC) posted quarterly Net Cash Flow of -$1.9 million for Q2 2026, down 559.9% year-over-year from $414000.0 in Q2 2025, and up 98.71% quarter-over-quarter from -$147.3 million in Q1 2026.
Fulcrum Therapeutics (FULC) Net Cash Flow (2018 - 2026) Analysis & Trends
Fulcrum Therapeutics (FULC) has reported Net Cash Flow for 9 consecutive years, with -$1.9 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Net Cash Flow fell 559.9% year-over-year to -$1.9 million; the TTM figure through Jun 2026 stood at $5.8 million (up 113.07% YoY), while the FY2025 annual figure was $139.3 million, up 325.3% from the prior year.
- Net Cash Flow improved to -$1.9 million in Q2 2026 per FULC's latest filing, from -$147.3 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $150.5 million in Q4 2025 and bottomed at -$147.3 million in Q1 2026.
- Historically, Net Cash Flow has averaged $725222.2 across 5 years, with a median of -$1.3 million in 2023.
- Annual changes were most pronounced in 2024 — Net Cash Flow jumped 6189.58% — and 2026, when it sank 818.5%.
- Fulcrum Therapeutics' Net Cash Flow stood at -$55.8 million in 2022, then surged by 91.91% to -$4.5 million in 2023, then plunged by 219.19% to -$14.4 million in 2024, then jumped by 1143.52% to $150.5 million in 2025, then tumbled by 101.27% to -$1.9 million in 2026.
- Business Quant data shows FULC's Net Cash Flow at -$1.9 million in Q2 2026, -$147.3 million in Q1 2026, and $150.5 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Fulcrum Therapeutics | 285.31 Mn | 285.31 Mn | - | -1.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.90 Mn |
| Jun 30, 2026 | -1.90 Mn |
| Mar 31, 2026 | -147.27 Mn |
| Mar 31, 2026 | -147.27 Mn |
| Dec 31, 2025 | 150.46 Mn |
| Dec 31, 2025 | 150.46 Mn |
| Sep 30, 2025 | 4.49 Mn |
| Sep 30, 2025 | 4.49 Mn |
| Jun 30, 2025 | 414,000.00 |
| Jun 30, 2025 | 414,000.00 |
| Mar 31, 2025 | -16.03 Mn |
| Mar 31, 2025 | -16.03 Mn |
| Dec 31, 2024 | -14.42 Mn |
| Dec 31, 2024 | -14.42 Mn |
| Sep 30, 2024 | -14.09 Mn |
| Sep 30, 2024 | -14.09 Mn |
| Jun 30, 2024 | 46.77 Mn |
| Jun 30, 2024 | 46.77 Mn |
| Mar 31, 2024 | 14.50 Mn |
| Mar 31, 2024 | 14.50 Mn |